!!! CYTOMYX !!! - Emerging Themes and Quantitative Metrics..... - 500 Beiträge pro Seite

[moz01]

Emerging Themes and Quantitative Metrics in High-Throughput Screening Space


Ausschnitt aus

http://atlas.pharmalicensing.com/features/disp/1060857367_3f…

.........Growth of cell-based screening in HTS. This was a consistent message at the conference. Companies in the exhibit area of the conference were pushing cell-based assay products, whether it was instrumentation (such as Amersham Biosciences [Piscataway, NJ, USA], Atto Bioscience [Rockville, MD, USA; with their high-throughput confocal systems for subcellular analysis], among others), or reagents (such as Cytomyx Ltd. [Cambridge, UK], DiscoveRx [Fremont, CA, USA], Bionaut Pharmaceuticals [Cambridge, MA, USA], among others).

There were many presentations focused on the use of cell-based assays from the vendors and end-users (pharmaceutical and biotechnology companies). There were several presentations focused on cell-based approaches in HTS at the conference. Presentations ranged from instrumentation that enabled intact cellular visualization and screening to optical manipulation of individual cells. In addition, much emphasis was placed on the different biologies for different target classes [discussed later in this section].

Multiplexed assays in HTS. This is another area of increasing importance across the entire HTS community. Robert Zivin from Johnson & Johnson Pharmaceutical Research & Development Exploratory Technology Group (New Brunswick, NJ, USA) presented a major talk on the opening day of the conference about their evaluation of various multiplexing technologies and the need to multiplex in early to late HTS.

Virtual Arrays (Sunnyvale, CA, USA), another company championing the use of multiplexing to increase information output in screening, presented a talk whereby they demonstrated how their system of "digital bar codes" could be used to multiplex important biological assays. They demonstrated how GPCR assays could be multiplexed using their platform--in this way, many different GPCRs could be screened simultaneously in the same experiment. We believe that the use of multiplexed HTS assays will impact the quantitative metrics of the HTS industry.

Assay technologies that are gaining traction in HTS. The use of functional assays in HTS is growing. The days in which the majority of the screens were binding events (receptorligand binding, for instance) and their perturbation by small drug-like molecules are gone. The use of functional assays in HTS enables the direct identification of ligands and the biological effect of compounds derived from libraries.

Some of the key biologies that are gaining traction within the drug discovery community address GPCRs. This is a very successful druggable target class, and the biologies utilize reporter genes, the measurement of molecules, such as cyclic AMP (that are a byproduct of signaling cascades), and the use of engineered cell lines that have embedded in them detection systems enabling biological readout upon activation of the GPCR.

Ion channels are a growing target class, and hence, assay methodologies for addressing this class is growing. Companies such as Cytomyx Ltd. were presenting their portfolio of ion channel-transfected cell lines for use in screening. In addition, companies such as Molecular Devices were presenting their high-throughput patch clamp platform, IonWorks™, designed for thousands of ion channel assay points per day.

Protein redistribution, translocation in vivo. The use of green fluorescent protein (GFP) as an intracellular protein sensor is now firmly established in the HTS community. The use of GFP as a way of annotating cellular pathways in vivo is an emerging area. Given that GFP is well studied and there are lots of colors of GFP available, there is increasing utilization of GFP as an assay choice for protein redistribution (localization) in vivo, protein-protein interactions, protease activity, calcium measurements, and kinase activity, among others.........

[jetti]

vielen dank jetzt werden wohl bald einige auf diese gen bio-perle aufmerksam

[mrbody]

[Ationrschulze]

@ 1 : Bitte übersetzten ! Danke !

@ all: Ist der Break Even nun geschafft ????

Bitte um ehrliche Antworten ! Danke !

[jetti]

mr........wolltest wohl preiswerter rein,wie

[mrbody]

#5

Wie bl.. bist Du eigentlich?

Wie oft denn noch? Warum sollte ich da rein wollen in die tote Bude???

Du jauelst schon seit Kursen um die 0,025 rum das ich da billig rein will! Das könnte ich ja heute oder? Aber in einem Monat würde ich denn nochmal bei weitem billiger reinkommen wenn ich wollte, was ich aber nicht tue...

Du bist ein kleiner Junge der seine Kohle in einen Titel gesteckt hat wo er nur mit Verlust rauskommt und deswegen hoffst Du und pusht und pusht und hoffst...

[Truck1]

Worldcom Ümsätze enorm
Aktie ++ 30 Prozent.Was kommt da wohl.

[mrbody]

#7

Nix, außer das Du Deine Kohle verlierst...

[jetti]

mr.......was hälst du denn so

[mrbody]

Das geht so einen kleinen Jungen gar nichts an...

[jetti]

cor ist wohl vor dem aus

[mrbody]

Du bist sowas von .......

Cortech ist schon lange tot und nur n leerer Mantel! Da liegt die Chance...

Oh Junge, geh nochmal in die Schule...

[propus]

@ jetti

ist nun der Break Even geschafft ????????????????????ß

Brauchst nur mit ja oder nein zu antworten.

Propus

[jetti]

im leeren mantel wohl wieder durch den park gelaufen...........man junge......auch dort ist tote hose

[sufukli]

@brobus
Nein.

[mrbody]

#13

Jetti weiß das doch nicht, der kann doch kein englisch...



So ich muß hier weg!

[mrbody]

0,018-0,022

[darkone]

Yetti du hast dich genug blamiert !! Gib auf !!

Ein paar werden ganz schön Sauer auf deine Pusherei sein

[Elrond]

@propus
das werden die nächsten Zahlen zeigen - die sollten eigentlich minütlich eintreffen

[jetti]

daß schnallt hier nur keiner,elle
auch england wartet noch

[atahualpa1]

London...NULL Umsatz ???

[Elrond]

hi jetti

ich muß mir die Zahlen noch genauer durchlesen - aber auf den 1. Blick nicht schlecht

- Umsatz verfünfacht
- Verlust von 886.000 (engl. Pfund) auf 414.000 halbiert
- 2 strategische Firmen-Neuerwerbungen -> die kosten schließlich auch was
- Restrukturierung im vollen Gange ( Einsparungen von 400.000 Pfund/Jahr )

CYTO positioniert sich neu
bald werden die Früchte geerntet

[jetti]

morgen leute,schon wer wach